Compare STHO & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STHO | SEER |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7M | 106.0M |
| IPO Year | N/A | 2020 |
| Metric | STHO | SEER |
|---|---|---|
| Price | $7.62 | $1.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.9K | ★ 180.1K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,547,000.00 | $16,376,999.00 |
| Revenue This Year | N/A | $22.37 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.11 |
| 52 Week Low | $6.06 | $1.62 |
| 52 Week High | $10.63 | $2.52 |
| Indicator | STHO | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 22.38 |
| Support Level | $7.56 | $1.85 |
| Resistance Level | $7.77 | $2.02 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 25.42 | 0.00 |
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.